China launched two new-generation satellites, Shijian-29A and Shijian-29B, on December 31, 2025, using a modified Long March-7 rocket from the Wenchang Space Launch Site, as reported by CGTN. This ...

Researchers at the Hefei Institutes of Physical Science of the Chinese Academy of Sciences have developed a new way to significantly enhance upconversion luminescence in oxide perovskites, a class of ...

Both therapeutics will leverage AGC Biologics’ BravoAAV suspension platform and use an innovative dual AAV vector approach, which splits the therapeutic gene into 2 halves. AAVantgarde and AGC ...

AAVantgarde and AGC Biologics collaborate to manufacture dual-vector gene therapies for inherited retinal disorders, AAVB-039 and AAVB-081. AAVantgarde secured $141 million in Series B funding to ...

General Chance Saltzman’s newly released Vector 2025 is the clearest articulation yet of the U.S. Space Force’s purpose, priorities, and philosophy. It captures the seriousness of today’s contested ...

This study addresses the challenges in teacher emotion recognition (TER), namely the lack of high-quality multimodal datasets and insufficient modeling of common and discriminative emotional features ...

Stacked dual displays are becoming more popular as people realise their ergonomic benefits compared to two side-by-side monitors, and where space is at a premium—say in a tight home-working space or ...

WASHINGTON, Sept 24 (Reuters) - NASA has tapped startup Katalyst to save a $500 million orbiting observatory from falling into Earth's atmosphere by launching a spacecraft meant to push it farther in ...

Even though traditional databases now support vector types, vector-native databases have the edge for AI development. Here’s how to choose. AI is turning the idea of a database on its head.

Patients in a Phase I/II clinical trial conducted by UMass Chan Medical School of a dual vector gene therapy for GM2 gangliosidosis, which includes Tay-Sachs and Sandhoff diseases, exhibited a ...

The molecule, developed in collaboration with Massachusetts-based Kailera Therapeutics, is headed for a new drug application in China and global clinical trials. Hengrui Pharma’s dual GLP-1/GIP ...